BRPI0809936A2 - Composto sulfonado de açúcar e uso do mesmo como medicamento - Google Patents

Composto sulfonado de açúcar e uso do mesmo como medicamento

Info

Publication number
BRPI0809936A2
BRPI0809936A2 BRPI0809936-7A2A BRPI0809936A BRPI0809936A2 BR PI0809936 A2 BRPI0809936 A2 BR PI0809936A2 BR PI0809936 A BRPI0809936 A BR PI0809936A BR PI0809936 A2 BRPI0809936 A2 BR PI0809936A2
Authority
BR
Brazil
Prior art keywords
medicinal product
sugar compound
sulfonated
sulfonated sugar
compound
Prior art date
Application number
BRPI0809936-7A2A
Other languages
English (en)
Inventor
Keisuke Ohta
Masahiko Miura
Kengo Sakaguchi
Fumio Sugawara
Noriyuki Sato
Hiroeki Sahara
Nobuaki Takahashi
Yoko Mori
Takayuki Yamazaki
Kazuyoshi Masaki
Hiroshi Murata
Original Assignee
Toyo Suisan Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Suisan Kaisha filed Critical Toyo Suisan Kaisha
Publication of BRPI0809936A2 publication Critical patent/BRPI0809936A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0809936-7A2A 2007-07-20 2008-07-18 Composto sulfonado de açúcar e uso do mesmo como medicamento BRPI0809936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007190120 2007-07-20
PCT/JP2008/063056 WO2009014101A1 (ja) 2007-07-20 2008-07-18 新規なスルホン酸化糖誘導体およびその医薬としての使用

Publications (1)

Publication Number Publication Date
BRPI0809936A2 true BRPI0809936A2 (pt) 2014-10-07

Family

ID=40281352

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809936-7A2A BRPI0809936A2 (pt) 2007-07-20 2008-07-18 Composto sulfonado de açúcar e uso do mesmo como medicamento

Country Status (10)

Country Link
US (2) US7973145B2 (pt)
EP (1) EP2130834A4 (pt)
JP (1) JP4435861B2 (pt)
KR (1) KR101136601B1 (pt)
CN (1) CN101641365B (pt)
AU (1) AU2008278337B2 (pt)
BR (1) BRPI0809936A2 (pt)
CA (1) CA2679915C (pt)
EA (1) EA016931B1 (pt)
WO (1) WO2009014101A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CN106380400B (zh) * 2016-02-04 2018-12-11 浙江省中医药研究院 一种萜品烯醇类化合物及其制备方法和应用
JP6621158B1 (ja) * 2019-03-05 2019-12-18 株式会社エム・ティー・スリー 放射線増感剤
JP6903273B1 (ja) 2020-09-25 2021-07-14 株式会社エム・ティー・スリー 化合物又はその塩、及び放射性増感剤
CN117860899A (zh) * 2022-10-11 2024-04-12 M.T.3株式会社 化合物或其药学上可接受的盐制备用于治疗癌症的药物组合物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113210T1 (de) * 1989-08-15 1994-11-15 Us Health Antivirale zusammensetzungen enthaltend sulfoquinovosylglycerolderivate und analoge davon.
JP4454051B2 (ja) * 1997-01-24 2010-04-21 東洋水産株式会社 新規な糖脂質、その製造方法及びその用途
JP4224429B2 (ja) * 1998-09-04 2009-02-12 東洋水産株式会社 スルホキノボシルアシルグリセロール
JP3851461B2 (ja) * 1998-09-04 2006-11-29 東洋水産株式会社 ピラノシドおよびその製造方法
CN1151795C (zh) * 1999-02-26 2004-06-02 东洋水产株式会社 含(磺基吡喃糖基)酰基甘油衍生物的药品
US6518410B2 (en) * 1999-02-26 2003-02-11 Toyo Suisan Kaisha, Ltd. Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments
ES2234568T3 (es) * 1999-03-11 2005-07-01 Toyo Suisan Kaisha, Ltd. Uso de derivados de sulfoquinovesidialcilglicerol como agentes inmunosupresores.
JP4913289B2 (ja) * 2001-05-23 2012-04-11 備前化成株式会社 カスパーゼ阻害剤
JP4281377B2 (ja) 2003-02-26 2009-06-17 東レ株式会社 液晶性ポリエステルおよびその組成物
EA010292B1 (ru) * 2004-06-24 2008-08-29 Тойо Суйсан Кайся, Лтд. Радиосенсибилизатор

Also Published As

Publication number Publication date
CN101641365B (zh) 2013-01-16
EP2130834A4 (en) 2012-09-05
CN101641365A (zh) 2010-02-03
AU2008278337A1 (en) 2009-01-29
KR101136601B1 (ko) 2012-04-23
AU2008278337B2 (en) 2011-09-29
WO2009014101A1 (ja) 2009-01-29
CA2679915C (en) 2012-10-30
JPWO2009014101A1 (ja) 2010-10-07
CA2679915A1 (en) 2009-01-29
US20090209475A1 (en) 2009-08-20
EP2130834A1 (en) 2009-12-09
KR20090122451A (ko) 2009-11-30
EA200970779A1 (ru) 2010-04-30
US20100298246A1 (en) 2010-11-25
EA016931B1 (ru) 2012-08-30
JP4435861B2 (ja) 2010-03-24
US7973145B2 (en) 2011-07-05

Similar Documents

Publication Publication Date Title
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
BRPI0819073A2 (pt) fralda descartável
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0821668A2 (pt) Uso
BRPI0807453A2 (pt) Preparação sólida
BRPI0820381A2 (pt) Formulações farmacêuticas
DK3090730T3 (da) Tabletter omfattende eltrombopag-olamin
DK2151438T3 (da) Lægemiddel indeholdende PPAR-Deltaagonist
BRPI0817310A2 (pt) Ensaio de monitoramento de fármaco
ATE493119T1 (de) Pharmazeutische zusammensetzung
DK2125048T3 (da) Præparat
BRPI0819071A2 (pt) fralda descartável
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
DK2182988T3 (da) Radiofarmaceutisk præparat
EP2197448A4 (en) dosing schedule
BRPI1015943A2 (pt) derivados de 1,2,3,4-tetra - hidro - pirimido [1,2-a] pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
BRPI0920502A2 (pt) compostos cicloundecadepsipeptídeos e seu uso como medicamento
BRPI0720309A2 (pt) Análogos de epotilona modificados nas posições c12 - c13 como fármacos anticâncer
BRPI0906727A2 (pt) Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
BRPI0907486A2 (pt) Triazolpiridazinas como inibidores de par1, sua produção e uso como medicamentos
BRPI0809936A2 (pt) Composto sulfonado de açúcar e uso do mesmo como medicamento
BRPI0813937A2 (pt) Derivado de 17beta-ciano-19-nor-andros-4-eno, seu uso e medicamentos contendo o derivado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.